Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
Authors
Keywords
-
Journal
JACC-Heart Failure
Volume 9, Issue 1, Pages 13-24
Publisher
Elsevier BV
Online
2020-11-12
DOI
10.1016/j.jchf.2020.08.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF
- (2019) Michael R. Zile et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
- (2019) Scott D. Solomon et al. CIRCULATION
- Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
- (2018) Gianluigi Savarese et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
- (2018) Paul K. Whelton et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
- (2018) Milton Packer et al. Lancet Diabetes & Endocrinology
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
- (2017) Clyde W. Yancy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril
- (2017) Akshay S. Desai et al. JAMA Cardiology
- Reduced Cardiac Index Is Not the Dominant Driver of Renal Dysfunction in Heart Failure
- (2016) Jennifer S. Hanberg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
- (2015) Adriaan A. Voors et al. EUROPEAN JOURNAL OF HEART FAILURE
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
- (2015) Bryan Williams et al. LANCET
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Neprilysin inhibition in chronic kidney disease
- (2014) P. Judge et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure
- (2009) Wilfried Mullens et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More